A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)

Trial Profile

A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms SAXAPCOS
  • Most Recent Events

    • 12 Jun 2018 Planned primary completion date changed from 8 Jul 2020 to 8 Sep 2020.
    • 12 Jun 2018 Planned initiation date changed from 2 Jul 2018 to 2 Sep 2018.
    • 29 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top